Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1987 3
1988 2
1989 9
1990 17
1991 11
1992 1
1993 5
1994 7
1995 11
1996 12
1997 3
1998 5
1999 10
2000 6
2001 12
2002 9
2003 10
2004 4
2005 3
2006 7
2007 1
2008 1
2009 2
2010 2
2011 2
2012 4
2013 3
2014 7
2015 5
2016 1
2018 2
2020 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

173 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Combined oral contraceptives: venous thrombosis.
de Bastos M, Stegeman BH, Rosendaal FR, Van Hylckama Vlieg A, Helmerhorst FM, Stijnen T, Dekkers OM. de Bastos M, et al. Cochrane Database Syst Rev. 2014 Mar 3;2014(3):CD010813. doi: 10.1002/14651858.CD010813.pub2. Cochrane Database Syst Rev. 2014. PMID: 24590565 Free PMC article. Review.
A dose related effect of ethinylestradiol was observed for gestodene, desogestrel, and levonorgestrel, with higher doses being associated with higher thrombosis risk. ...Risk of venous thrombosis for combined oral contraceptives with 30-35 mug ethinylestradiol and gesto
A dose related effect of ethinylestradiol was observed for gestodene, desogestrel, and levonorgestrel, with higher doses being associ …
A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception.
Dragoman MV, Tepper NK, Fu R, Curtis KM, Chou R, Gaffield ME. Dragoman MV, et al. Int J Gynaecol Obstet. 2018 Jun;141(3):287-294. doi: 10.1002/ijgo.12455. Epub 2018 Feb 22. Int J Gynaecol Obstet. 2018. PMID: 29388678 Free PMC article. Review.
The use of COCs containing cyproterone acetate, desogestrel, drospirenone, or gestodene was associated with a significantly increased risk of VTE compared with the use of levonorgestrel-containing COCs (pooled risk ratios 1.5-2.0). ...
The use of COCs containing cyproterone acetate, desogestrel, drospirenone, or gestodene was associated with a significantly increased …
Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis.
Stegeman BH, de Bastos M, Rosendaal FR, van Hylckama Vlieg A, Helmerhorst FM, Stijnen T, Dekkers OM. Stegeman BH, et al. BMJ. 2013 Sep 12;347:f5298. doi: 10.1136/bmj.f5298. BMJ. 2013. PMID: 24030561 Free PMC article. Review.
The relative risk of venous thrombosis for combined oral contraceptives with 30-35 g ethinylestradiol and gestodene, desogestrel, cyproterone acetate, or drospirenone were similar and about 50-80% higher than for combined oral contraceptives with levonorgestrel. A dose rel …
The relative risk of venous thrombosis for combined oral contraceptives with 30-35 g ethinylestradiol and gestodene, desogestrel, cyp …
A comparison of cycle control and effect on well-being of monophasic gestodene-, triphasic gestodene- and monophasic desogestrel-containing oral contraceptives. Gestodene Study Group.
Bruni V, Croxatto H, De La Cruz J, Dhont M, Durlot F, Fernandes MT, Andrade RP, Weisberg E, Rhoa M. Bruni V, et al. Gynecol Endocrinol. 2000 Apr;14(2):90-8. doi: 10.3109/09513590009167666. Gynecol Endocrinol. 2000. PMID: 10836195 Clinical Trial.

This was an open-label multicenter study to compare the cycle control and effect on well-being of two oral contraceptives containing gestodene and one containing desogestrel. A total of 2419 healthy women < or = 41 years of age were randomized to receive oral contracept

This was an open-label multicenter study to compare the cycle control and effect on well-being of two oral contraceptives containing gest
The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel.
Orme M, Back DJ, Ward S, Green S. Orme M, et al. Contraception. 1991 Apr;43(4):305-16. doi: 10.1016/0010-7824(91)90069-r. Contraception. 1991. PMID: 1830266 Clinical Trial.
With either gestodene or desogestrel present, the AUC of EE2 was not significantly different from that found when EE2 was given alone. In addition, there was no significant difference between EE2 + gestodene and EE2 + desogestrel. Comparing the relative oral and iv …
With either gestodene or desogestrel present, the AUC of EE2 was not significantly different from that found when EE2 was given alone …
Comparison of two triphasic oral contraceptives containing either gestodene or norethindrone: a randomized, controlled trial.
Weber-Diehl F, Lehnert J, Lachnit U. Weber-Diehl F, et al. Contraception. 1993 Oct;48(4):291-301. doi: 10.1016/0010-7824(93)90076-j. Contraception. 1993. PMID: 8222658 Clinical Trial.
On the other hand, breakthrough bleeding occurred less often in women in the gestodene group (19.3% vs. 29.6%). Over time, women in the norethindrone group were more likely to gain more than 2 kg than those in the gestodene group. ...Weight gain and acne were less c …
On the other hand, breakthrough bleeding occurred less often in women in the gestodene group (19.3% vs. 29.6%). Over time, women in t …
The effect of desogestrel, gestodene, and other factors on spotting and bleeding.
Rosenberg MJ, Waugh MS, Higgins JE. Rosenberg MJ, et al. Contraception. 1996 Feb;53(2):85-90. doi: 10.1016/0010-7824(95)00270-7. Contraception. 1996. PMID: 8838484 Clinical Trial.
Spotting and bleeding are among the most common side effects associated with oral contraceptive (OC) use and their occurrence is a prime determinant of whether a new user will continue to use OCs. Desogestrel and gestodene are two new progestins that were developed in part …
Spotting and bleeding are among the most common side effects associated with oral contraceptive (OC) use and their occurrence is a prime det …
Clinical and metabolic effects of gestodene and levonorgestrel.
Rabe T, Runnebaum B, Kohlmeier M, Harenberg J, Weicker H. Rabe T, et al. Int J Fertil. 1987;32 Suppl:29-44. Int J Fertil. 1987. PMID: 2906345 Clinical Trial.
The new low-dose combination oral contraceptive (OC) containing 75 micrograms of the new progestogen gestodene (GTD) plus 30 micrograms ethinyl estradiol (EE) was clinically tested and compared with a levonorgestrel (LNG) combined pill (150 micrograms LNG plus 30 microgram …
The new low-dose combination oral contraceptive (OC) containing 75 micrograms of the new progestogen gestodene (GTD) plus 30 microgra …
Gestodene and desogestrel do not have a different influence on concentration profiles of ethinylestradiol in women taking oral contraceptives--results of isotope dilution mass spectrometry measurements.
Siekmann L, Siekmann A, Bidlingmaier F, Brill K, Albring M. Siekmann L, et al. Eur J Endocrinol. 1998 Aug;139(2):167-77. doi: 10.1530/eje.0.1390167. Eur J Endocrinol. 1998. PMID: 9724072 Clinical Trial.
After the administration of 30 microg EE2 combined with 75 microg gestodene (EE2/GSD) or 150 microg desogestrel (EE2/DES), blood samples were taken from the subjects on certain days and in certain previously specified cycles in the course of 12 h after medication. ...
After the administration of 30 microg EE2 combined with 75 microg gestodene (EE2/GSD) or 150 microg desogestrel (EE2/DES), blood samp …
Serum distribution of two contraceptive progestins: 3-ketodesogestrel and gestodene.
Hammond GL, Bocchinfuso WP, Orava M, Smith CL, van den Ende A, van Enk A. Hammond GL, et al. Contraception. 1994 Oct;50(4):301-18. doi: 10.1016/0010-7824(94)90018-3. Contraception. 1994. PMID: 7813219 Clinical Trial.
The proportion of gestodene bound to SHBG was consistently higher than that observed for 3-ketodesogestrel, and this undoubtedly reflects the higher affinity of SHBG for gestodene (Kd = 1.2 nM at 37 degrees C) when compared to 3-ketodesogestrel (Kd = 4.7 nM at 37 de …
The proportion of gestodene bound to SHBG was consistently higher than that observed for 3-ketodesogestrel, and this undoubtedly refl …
173 results